Semicarbazide-sensitive amine oxidase and kidney disease

2013 ◽  
Vol 305 (12) ◽  
pp. F1637-F1644 ◽  
Author(s):  
May Y. W. Wong ◽  
Sonia Saad ◽  
Carol Pollock ◽  
Muh Geot Wong

With better understanding of the molecular mechanisms underpinning chronic kidney disease, the roles of inflammation and fibrosis are becoming increasingly inseparable. The progression of renal disease is characterized by pathomorphological changes that consist of early inflammatory responses followed by tubulointerstitial fibrosis, tubular atrophy, and glomerular and vascular sclerosis. Currently available therapies that reduce hypertension, proteinuria, hyperglycemia, and interruption of the renin-angiotensin-aldosterone system are at best only partially effective. Hence, there remains a need to explore agents targeting nonrenin-angiotensin-aldosterone system pathways. In this review, we discuss mechanistic aspects in the physiological and pathological role of semicarbazide-sensitive amine oxidase, a protein enzyme involved in cellular trafficking and inflammation, with respect to the kidney. We explore the evidence for the use of semicarbazide-sensitive amine oxidase inhibitors as potential agents in renal fibrosis to delay the onset and progression of chronic kidney disease.

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Shulin Li ◽  
Fei Wang ◽  
Dong Sun

AbstractChronic kidney disease (CKD) affects 8–16% of the population worldwide and is characterized by fibrotic processes. Understanding the cellular and molecular mechanisms underpinning renal fibrosis is critical to the development of new therapeutics. Microvascular injury is considered an important contributor to renal progressive diseases. Vascular endothelium plays a significant role in responding to physical and chemical signals by generating factors that help maintain normal vascular tone, inhibit leukocyte adhesion and platelet aggregation, and suppress smooth muscle cell proliferation. Loss of the rich capillary network results in endothelial dysfunction, hypoxia, and inflammatory and oxidative effects and further leads to the imbalance of pro- and antiangiogenic factors, endothelial cell apoptosis and endothelial-mesenchymal transition. New techniques, including both invasive and noninvasive techniques, offer multiple methods to observe and monitor renal microcirculation and guide targeted therapeutic strategies. A better understanding of the role of endothelium in CKD will help in the development of effective interventions for renal microcirculation improvement. This review focuses on the role of microvascular injury in CKD, the methods to detect microvessels and the novel treatments to ameliorate renal fibrosis.


Author(s):  
Anna Faivre ◽  
Carsten C Scholz ◽  
Sophie de Seigneux

Abstract Chronic kidney disease (CKD) is defined as an alteration of kidney structure and/or function lasting for >3 months [1]. CKD affects 10% of the general adult population and is responsible for large healthcare costs [2]. Since the end of the last century, the role of hypoxia in CKD progression has controversially been discussed. To date, there is evidence of the presence of hypoxia in late-stage renal disease, but we lack time-course evidence, stage correlation and also spatial co-localization with fibrotic lesions to ensure its causative role. The classical view of hypoxia in CKD progression is that it is caused by peritubular capillary alterations, renal anaemia and increased oxygen consumption regardless of the primary injury. In this classical view, hypoxia is assumed to further induce pro-fibrotic and pro-inflammatory responses, as well as oxidative stress, leading to CKD worsening as part of a vicious circle. However, recent investigations tend to question this paradigm, and both the presence of hypoxia and its role in CKD progression are still not clearly demonstrated. Hypoxia-inducible factor (HIF) is the main transcriptional regulator of the hypoxia response. Genetic HIF modulation leads to variable effects on CKD progression in different murine models. In contrast, pharmacological modulation of the HIF pathway [i.e. by HIF hydroxylase inhibitors (HIs)] appears to be generally protective against fibrosis progression experimentally. We here review the existing literature on the role of hypoxia, the HIF pathway and HIF HIs in CKD progression and summarize the evidence that supports or rejects the hypoxia hypothesis, respectively.


2021 ◽  
Vol 12 ◽  
Author(s):  
Chunlan Ji ◽  
Yin Li ◽  
Yenan Mo ◽  
Zhaoyu Lu ◽  
Fuhua Lu ◽  
...  

Objectives: Trimethylamine N-oxide (TMAO), a metabolic product of gut flora, is increased in chronic kidney disease (CKD) subjects and is recognized as one type of uremic toxins which is associated with poor cardiovascular outcomes and kidney function loss. Previous studies have suggested that rhubarb enema could reduce circulating uremic toxins such as urea, creatinine, and indoxyl sulfate and also regulate the intestinal microbiota. However, whether rhubarb enema retards kidney dysfunction by reducing circulating TMAO and its underlying mechanism, are still unclear. The present study aims to investigate the impact of rhubarb enema on TMAO and its precursors, as well as on the intestinal microbiota in 5/6 nephrectomized (5/6Nx) CKD rats.Design: Rats in the treatment groups were given rhubarb enema after modeling. At the end of the study, blood, feces, and kidney tissues were collected and processed for biochemical analyses, histological and western blot analyses, 16S rRNA sequence and untargeted metabolomic analyses.Results: Rhubarb enema reduced serum TMAO and trimethylamine (TMA) levels, inhibited the expression of inflammatory markers (interleukin-6, tumor necrosis factor α and Interferon-γ) and alleviated tubular atrophy, monocyte infiltration and interstitial fibrosis in 5/6Nx CKD rats. Moreover, rhubarb enema significantly increased the abundance of some symbiotic bacteria and probiotics, while reduced the abundance of some potential pathogens at the genus level. In addition, Spearman’s correlation analysis revealed that lachnospiraceae and romboutsia were positively correlated with TMAO.Conclusion: Rhubarb enema decreases circulating TMAO level and improves renal fibrosis in 5/6Nx CKD rats, which may be related to the regulation of intestinal microbial community.


Life ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 315
Author(s):  
Carlo Maria Barbagallo ◽  
Angelo Baldassare Cefalù ◽  
Antonina Giammanco ◽  
Davide Noto ◽  
Rosalia Caldarella ◽  
...  

Chronic kidney disease (CKD) is one of the most important risk factors for cardiovascular disease (CVD). Despite the kidney having no direct implications for lipoproteins metabolism, advanced CKD dyslipidemia is usually present in patients with CKD, and the frequent lipid and lipoprotein alterations occurring in these patients play a role of primary importance in the development of CVD. Although hypertriglyceridemia is the main disorder, a number of lipoprotein abnormalities occur in these patients. Different enzymes pathways and proteins involved in lipoprotein metabolism are impaired in CKD. In addition, treatment of uremia may modify the expression of lipoprotein pattern as well as determine acute changes. In renal transplantation recipients, the main lipid alteration is hypercholesterolemia, while hypertriglyceridemia is less pronounced. In this review we have analyzed lipid and lipoprotein disturbances in CKD and also their relationship with progression of renal disease. Hypolipidemic treatments may also change the natural history of CVD in CKD patients and may represent important strategies in the management of CKD patients.


2021 ◽  
Vol 12 ◽  
Author(s):  
Difei Zhang ◽  
Bingran Liu ◽  
Xina Jie ◽  
Jiankun Deng ◽  
Zhaoyu Lu ◽  
...  

Chronic kidney disease (CKD) is a leading public health problem with high morbidity and mortality, but the therapies remain limited. Bupi Yishen Formula (BYF) - a patent traditional Chinese medicine (TCM) formula - has been proved to be effective for CKD treatment in a high-quality clinical trial. However, BYF’s underlying mechanism is unclear. Thus, we aimed to reveal BYF pharmacological mechanism against CKD by network pharmacology and experimental studies. Network pharmacology-based analysis of the drug-compound-target interaction was used to predict the potential pharmacological mechanism and biological basis of BYF. We performed a comprehensive study by detecting the expression levels of fibrotic and inflammatory markers and main molecules of candidate signal pathway in adenine-induced CKD rats and TGF-β1-induced HK-2 cells with the treatment of BYF by western blotting and RT-qPCR analyses. Using small interfering RNA, we assessed the effect of BYF on the TLR4-mediated NF-κB mechanism for CKD renal fibrosis and inflammation. Network pharmacology analysis results identified 369 common targets from BYF and CKD. Based on these common targets, the BYF intervention pathway was analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. We found that Toll-like receptor (TLR) and NF-κB signaling pathways were enriched. Then, we demonstrated that BYF significantly improved the adenine-induced CKD rat model condition by kidney dysfunction improvement and reversing renal fibrosis and inflammation. Subsequently, we investigated BYF’s effect on the TLR4/NF-κB signaling pathway. We found that TLR4 and phospho-NF-κB (p-p65 and p-IKβα) expression was significantly upregulated in adenine-induced CKD rats, then partially downregulated by BYF. Furthermore, BYF inhibited fibrotic and inflammatory responses, as well as TLR4, p-p65, and p-IKβα in TGF-β1-induced HK-2 cells. Additionally, the BYF inhibitory effect on fibrosis and inflammation, and NF-κB pathway activation were significantly reduced in TGF-β1-induced HK-2 cells transfected with TLR4 siRNA. Altogether, these findings demonstrated that the suppression of TLR4-mediated NF-κB signaling was an important anti-fibrotic and anti-inflammatory mechanism for BYF against CKD. It also provided a molecular basis for new CKD treatment drug candidates.


2021 ◽  
Vol 12 ◽  
Author(s):  
Myriam Dao ◽  
Helene François

Chronic kidney disease (CKD) concerns millions of individuals worldwide, with few therapeutic strategies available to date. Recent evidence suggests that the endocannabinoid system (ECS) could be a new therapeutic target to prevent CKD. ECS combines receptors, cannabinoid receptor type 1 (CB1R) and type 2 (CB2R), and ligands. The most prominent receptor within the kidney is CB1R, its endogenous local ligands being anandamide and 2-arachidonoylglycerol. Therefore, the present review focuses on the therapeutic potential of CB1R and not CB2R. In the normal kidney, CB1R is expressed in many cell types, especially in the vasculature where it contributes to the regulation of renal hemodynamics. CB1R could also participate to water and sodium balance and to blood pressure regulation but its precise role remains to decipher. CB1R promotes renal fibrosis in both metabolic and non-metabolic nephropathies. In metabolic syndrome, obesity and diabetes, CB1R inhibition not only improves metabolic parameters, but also exerts a direct role in preventing renal fibrosis. In non-metabolic nephropathies, its inhibition reduces the development of renal fibrosis. There is a growing interest of the industry to develop new CB1R antagonists without central nervous side-effects. Experimental data on renal fibrosis are encouraging and some molecules are currently under early-stage clinical phases (phases I and IIa studies). In the present review, we will first describe the role of the endocannabinoid receptors, especially CB1R, in renal physiology. We will next explore the role of endocannabinoid receptors in both metabolic and non-metabolic CKD and renal fibrosis. Finally, we will discuss the therapeutic potential of CB1R inhibition using the new pharmacological approaches. Overall, the new pharmacological blockers of CB1R could provide an additional therapeutic toolbox in the management of CKD and renal fibrosis from both metabolic and non-metabolic origin.


2020 ◽  
Author(s):  
He Liu ◽  
Dan Gao ◽  
Yuanbo Sun ◽  
Fengqiong Tang ◽  
Mingcheng Hu ◽  
...  

Abstract Background Chronic kidney disease (CKD) can lead to systemic inflammatory responses and other cardiovascular disease. Diffusion tensor imaging findings generated by gadolinium-based MRI (DTI-GBMRI) is regarded as a standard method for assessing the pathology of CKD. To evaluate the diagnostic value of DTI-MRI for renal histopathology and renal efficiency, renal fibrosis and damage, noninvasive quantification of renal blood flow (RBF) were investigated in patients with CKD.Methods CKD patients (n = 186) were recruited and underwent diagnosis of renal DTI-GBMRI or DTI-MRI to identify the pathological characteristics and depict renal efficiency. The cortical RBFs and estimated glomerular filtration rate (eGFR) were compared in CKD patients undergone DTI-GBMRI (n=92) or DTI-MRI (n=94). Results Results showed that gadolinium enhanced the diagnosis generated by DTI-MRI in renal fibrosis, renal damage and eGFR. The superiority in sensitivity and accuracy of DTI-GBMRI method in assessing renal function and evaluating renal impairment was observed in CKD patients compared with DTI-MRI. Outcomes demonstrated that DTI-GBMRI had higher accuracy, sensitivity and specificity than DTI-MRI in diagnosing patients with CKD. Conclusions In conclusion, these outcomes indicate that DTI-GBMRI is a potential noninvasive method for measuring renal function, which can provide valuable information for clinical CKD diagnosis (Trial registration number: ChiCTR-IPR-16010073, 02/12/2016, registered status).


2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Sharma Pravesh ◽  
Kalyani Karnam ◽  
Kavita Sedmaki ◽  
Kirti Hira ◽  
Onkar Prakash Kulkarni

Abstract Background and Aims Role of epigenetic factors like histone deacetylases (HDACs) is largely unexplored in the pathogenesis of Nephrocalcinosis-related chronic kidney disease. The present study was performed to evaluate the functional role of HDAC5 in fibroblast activation in in-vitro and in a mouse model of Nephrocalcinosis-related chronic kidney disease. Method C57BL/6 male mice (6-7weeks old) were procured from registered CPCSEA breeder (Hyderabad, India), NRK49F cell line were generously provided by NCCS (Pune, India). All experimental procedures were approved by the animal ethics committee of the institute. Nephrolithiasis (oxalate nephropathy) was induced by feeding oxalate rich diet (Ssniff, Soest, Germany) to C57/BL6 mice for 10 days. NRK49F cells were stimulated with LPS (1µg/ml) for 2hrs followed by TGF-β (25ng/ml) for 24hrs. To achieve HDAC5 knockdown, the cells were pre-incubated with HDAC5 specific siRNA for 24hrs before stimulating with LPS. In another set of experiment, cells were incubated with 4-sodium phenyl butyrate(PBA) a non-selective HDAC5 and HDAC4 inhibitor at a dose of 1mM. 24 hrs after LPS stimulation cell lysates were analysed for protein expression of α-SMA, Collagen1a, KLF2, NLRP3, HDAC5 and β-actin. Mice fed with high oxalate diet were treated with PBA (500mg/kg) twice a day and on day 10 mice were sacrificed to analyse renal function and fibrosis parameters. Mice kidney tissues were analysed for crystal deposition (pizaalato staining), renal fibrosis (Picrosirius staining), and renal histology (H&E staining). The fibrosis markers were analysed by RT-PCR and immunoblotting. Renal function was determined by plasma BUN and creatinine analysis. Diet containing high oxalate with calcium was provided to mice in the control diet group (negative diet control). Results Renal fibroblasts (NRK 49F) stimulated with LPS and TGF-β showed upregulation of HDAC5, NLRP3, α-SMA, and Collagen-1a. Depletion of HDAC5 expression with HDAC5 siRNA significantly reduced expression of NLRP-3, α-SMA, and Collagen-1 in stimulated NRK49F cells. The expression of KLF2 in HDAC5 depleted cells was found to be upregulated. PBA treatment also reduced the expression of HDAC5 in NRK49F cells and had significant reduction in the expression of NLRP3 along with fibroblast activation markers, while KLF-2 expression was found to be up-regulated. Similar to our observation in stimulated renal fibroblasts, the expression of HDAC5 was found to be upregulated in mouse model of oxalate nephropathy. Treatment with PBA showed significant downregulation of HDAC5 in kidneys of the mice fed with high oxalate diet. Mice treated with PBA showed down regulated renal expression of NLRP3, Collagen1a, α-SMA, TGF-β in comparison to vehicle treated mice. Treatment with PBA showed significant upregulation of KLF2 expression in kidney. PBA treated mice showed significant renal protection during nephrolithiasis as indicated by reduced plasma BUN and creatinine levels. Oxalate crystal deposition index was similar in all high oxalate diet groups. PBA treatment showed overall better renal histological protection observed through H&E (reduced tubular injury score) and picrosirius staining (reduced collagen deposition). Conclusion HDAC5 knockdown or HDAC5 inhibition with PBA attenuates fibroblasts activation by inhibiting NLRP3 expression. Treatment with PBA in mice with Nephrocalcinosis-related chronic kidney disease showed significant protection against renal fibrosis with downregulation of NLRP3 expression. We propose HDAC5 as a novel regulator of fibroblast activation in Nephrocalcinosis-related chronic kidney disease.


2019 ◽  
Vol 3 (9) ◽  
Author(s):  
Rattiyaporn Kanlaya ◽  
Visith Thongboonkerd

ABSTRACT Chronic kidney disease (CKD) is a common public health problem worldwide characterized by gradual decline of renal function over months/years accompanied by renal fibrosis and failure in tissue wound healing after sustained injury. Patients with CKD frequently present with profound signs/symptoms that require medical treatment, mostly culminating in hemodialysis and renal transplantation. To prevent CKD more efficiently, there is an urgent need for better understanding of the pathogenic mechanisms and molecular pathways of the disease pathogenesis and progression, and for developing novel therapeutic targets. Recently, several lines of evidence have shown that epigallocatechin-3-gallate (EGCG), an abundant phytochemical polyphenol derived from Camellia sinensis, might be a promising bioactive compound for prevention of CKD development/progression. This review summarizes current knowledge of molecular mechanisms underlying renoprotective roles of EGCG in CKD based on available preclinical evidence (from both in vitro and in vivo animal studies), particularly its antioxidant property through preservation of mitochondrial function and activation of Nrf2 (nuclear factor erythroid 2-related factor 2)/HO-1 (heme oxygenase-1) signaling, anti-inflammatory activity, and protective effect against epithelial mesenchymal transition. Finally, future perspectives, challenges, and concerns regarding its clinical use in CKD and renal fibrosis are discussed.


2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Estefanía Vázquez-Méndez ◽  
Yanet Gutiérrez-Mercado ◽  
Edgar Mendieta-Condado ◽  
Francisco Javier Gálvez-Gastélum ◽  
Hugo Esquivel-Solís ◽  
...  

Chronic kidney disease (CKD) causes anemia by renal damage. In CKD, the kidney is submitted to hypoxia, persistent inflammation, leading to fibrosis and permanent loss of renal function. Human recombinant erythropoietin (rEPO) has been widely used to treat CKD-associated anemia and is known to possess organ-protective properties that are independent from its well-established hematopoietic effects. Nonhematopoietic effects of EPO are mediated by an alternative receptor that is proposed to consist of a heterocomplex between the erythropoietin receptor (EPOR) and the beta common receptor (βcR). The present study explored the effects of rEPO to prevent renal fibrosis in adenine-induced chronic kidney disease (Ad-CKD) and their association with the expression of the heterodimer EPOR/βcR. Male Wistar rats were randomized to control group (CTL), adenine-fed rats (Ad-CKD), and Ad-CKD with treatment of rEPO (1050 IU/kg, once weekly for 4 weeks). Ad-CKD rats exhibited anemia, uremia, decreased renal function, increased infiltration of inflammatory cells, tubular atrophy, and fibrosis. rEPO treatment not only corrected anemia but reduced uremia and partially improved renal function as well. In addition, we observed that rEPO diminishes tubular injury, prevents fibrosis deposition, and induces the EPOR/βcR heteroreceptor. The findings may explain the extrahematopoietic effects of rEPO in CKD and provide new strategies for the treatment of renal fibrosis in CKD.


Sign in / Sign up

Export Citation Format

Share Document